Robocath in a few words

Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer thanks to reliable technologies, while complementing manual interventions.
R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed.
R-One™ is designed to operate with precision and perform specific movements, creating better interventional conditions. Thanks to its open architecture, R-One™ is compatible with
market-leading devices and cath labs.
In a prospective, randomized, controlled pre-clinical trial, R-One™ demonstrated safety and efficacy as it achieved 100% technical procedure success and no MACE (Major adverse cardiovascular events). R-One™ received the CE marking in February 2019 and started its clinical application in September 2019. Currently R-One™ is available in Europe and Africa.
Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all.
Based in Rouen, France, Robocath has more than 70 employees.


Company foundation
First in vivo tests
ISO 13485 certification granted
Industrial prototype
Safety-Efficacy study
R-One pre-launch and First-In-Man procedures
First remote procedure (120 km)
R-Evolution study conclusion

Robocath in the world

19 Rue Marie Curie, Rouen, France


A doctor of medicine and a graduate of the 'Healthcare Industry Strategy and Management' program at ESSEC Business School, Philippe Bencteux has over twenty years of experience in vascular imaging. A trained neuro-radiologist, he founded Robocath in 2009 on the basis of the promising preliminary research carried out in collaboration with two engineering schools. He has since contributed his expertise in the medical sector to the company and is actively involved in the conception of new robotics solutions.
Holding a master’s degree in Business, Lucien Goffart started his career in 1999 at Johnson & Johnson Inc. Then, he joined Abbott before holding different positions at Volcano company between 2004 and 2011. From 2012 to 2014, he held different executive positions at Stentys and Mitralgin. Last four years, he served Boston Scientific as Business Unit Manager France. In the meanwhile, he was Board member of several companies from the Medtech industry such as Opsens Medical. Since 2019, he is Board member of Electroducer and was appointed CEO of Robocath in September.
Bruno Fournier is a trained engineer (Supélec) and Doctor of Science (Université Paris VI), with strong R&D experience in the healthcare sector. He led the development of products with high added value in several fields (ultrasound, bone density measurement, respiratory support, etc.). Passionate about new medical technologies, he joined Robocath in 2012 after management roles with the Air Liquide Groupe and his time as Director of R&D at one of Getinge Group subsidiary from 2006 to 2012.
François Oechsel holds a first Master's degree in Biomechanics and a second in Mechanical Engineering. He has 20 years of experience in technical development and procurement. He started his career at Aptar in 1994, where he was a project manager, before holding management positions in purchasing and then packaging in companies such as Boehringer Ingelheim, Delpharm or Johnson & Johnson. He joined Robocath in March 2022.
A graduate of the Institut Supérieur d'Ingénieurs de Franche-Comté in biomedical engineering since 2013, Clémentine Liard joined Robocath as an intern in 2012, before gradually moving up the ranks of the Quality and Regulatory Affairs division, of which she is now the director. She also leads the various clinical endeavors.

Strategic Committee

Mr. Jonathan Chen is the Chief International Business Officer of the MicroPort Scientific Corporation, Chairperson of Intercontinental CRM Committee, Co-Chairperson of InterContinental Orthopedics Committee and a member of the General Management Committee of MicroPort. Prior to current positions, he has served as the Executive Vice President of International Operations and Investor Relations of the Company. Mr. Chen's primary responsibilities include growing the company's International business in markets of the U.S, Europe, Asia Pacific and Latin America. Mr. Chen has over 23 years of experience in the medical device industry. Prior to joining the Company, Mr. Chen worked for Angiotech Pharmaceuticals, Inc. for 6 years, where he was Senior Vice President of Business Development & Financial Strategy. Prior to joining Angiotech, Mr. Chen was a life sciences investment banker for Credit Suisse and Alex. Brown & Sons.
Newly created by the CEA Investissement seasoned funds management team, CEA and Amundi, Supernova Invest is specialized in deep-tech venture capital in life sciences, energy and industry (electronics, advanced materials, instruments…).
Mr. Haitong Wang is managing partner at Zhejiang Silk Road Fund. Zhejiang Silk Road Fund is a Chinese private equity fund focusing on cross-border investments across various sectors, including healthcare, advanced manufacturing, TMT, and consumer. The fund is managed by Zhejiang United Investment Group (‘ZUIG’), an investment firm backed by eight Zhejiang-based entrepreneurs. ZUIG currently has about RMB 12 billion ($1.7b) assets under management and has offices in Hangzhou, Shanghai, Hong Kong, and Shenzhen.
An historic investor in Robocath (since 2013), NCI is a major player in capital investment in Normandy.
An historic investor in Robocath (since 2013), GO CAPITAL is an investment fund management company that favors companies with high growth potential in the fields of healthcare, technology (hardware and software), digital and innovative services.
Pr. Chao He (Alex) is general manager of Medbot, a MicroPort’s robotics subsidiary. Founded in 1998 in Shanghai (China) with the common belief that advancements in medical technology can transform patients’ lives, MicroPort is a global leading developer, manufacturer and operator focusing on minimally invasive intervention products for the treatment of vascular diseases and pathological changes. Over the last two decades, MicroPort has taken important steps towards fulfilling its mission of providing access to the best means of prolonging and reshaping lives and today provides over 300 devices and technologies, currently approved for use in nearly 10,000 hospitals worldwide. At MicroPort innovation is part of our DNA¸ not only in the treatments and services we develop but also in the way we foster innovation. With a vast global footprint of R&D and manufacturing sites (Shanghai; Memphis (TN) in the United States; Clamart in France; Saluggia in Italy; Santo Domingo in Dominican Republic), a strong focus on technology innovation with over 4,000 patent applications, and a global workforce of over 7,000 employees, MicroPort is committed to its vision of building a People Centric Consortium of companies focused on Emerging Medical Technologies.
Chantal Le Chat joined GE Healthcare in 1985 as an engineer. She then held various leadership roles in Engineering within the XRays tubes as well as the Vascular organization based in Buc (France) or Milwaukee (Wisconsin, US). In 2000, she moved to the Service organization, leading Service Operations for EMEA before becoming in 2002 the Service GM for France-Belgium-Luxemburg. In this role, she drove customer satisfaction, operational excellence and profitable growth. In 2005, Chantal was promoted to EMEA Product GM for Surgery, Interventional & XRays and successfully developed the business for five years. In 2010, she became the Global Segment GM for Premium Angiography and Hybrid-OR. In this role, she drove market creation as well as introduced disruptive products and applications such as the Discovery IGS 7 platform. In mid-14, she expanded her role to cover also the CardioVascular segment and became the Global GM for Interventional. Chantal holds an Engineering degree in Physics from the “Ecole Supérieure de Physique et Chimie Industrielles” (ESPCI) and a Master in Medical Instrumentations, Paris France – 1985.

Medical Advisory Board

• co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse, co-director of EuroPCR, one of the most important interventional cardiology congresses in the world. Director of the EAPCI, (European Association of Percutaneous Cardiovascular Interventions) between 2011 and 2014. He is the author of numerous publications and holds several major awards.
Pr. Haude has been head physician of the Medical Clinic I at the Clinic Neuss for 13 years and is thus also in charge of cardiology and of their cardiac catheter labs. In addition, Professor Haude has been involved in interventional cardiology for 31 years and has been past chairman of the Working Group on Interventional Cardiology (AGIK) at the German Society of Cardiology , PCR and ESC board member and EAPCI president from 2016 to 2018. He currently is an EAPCI board member, Pr. Haude has published more than 300 scientific articles.
Dr. Lorgat is an interventional cardiologist at Christiaan Barnard Memorial Hospital since 1998. As one of the first users of a robotic system for electrophysiology, Dr. Lorgat has performed more than 1,600 procedures with this robotic assistance over a period of 6 years and is an active research contributor in this field.


Rated as fourth Medical French Start-up
by Forbes Magazine
Winner of the TechInnov Award 2015
Nominee for "Trophée de l'Avenir" 2018
by Europe 1
Nominee for French Start-up of the year 2018
by EY